Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist (NCT06851858)

🧪 Interventions in This Study

• AZD6234 (DRUG)
• Placebo to match (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (18 Sites)

• Research Site — Birmingham, Alabama
• Research Site — Mobile, Alabama
• Research Site — Doral, Florida
• Research Site — Jacksonville, Florida
• Research Site — Miami, Florida
• Research Site — Miami, Florida
• Research Site — Winter Park, Florida
• Research Site — Canton, Georgia
• Research Site — Fayetteville, Georgia
• Research Site — Chicago, Illinois
• Research Site — Oak Brook, Illinois
• Research Site — Newton, Kansas
• Research Site — Lexington, Kentucky
• Research Site — Kansas City, Missouri
• Research Site — Las Vegas, Nevada
• Research Site — Norman, Oklahoma
• Research Site — Knoxville, Tennessee
• Research Site — San Antonio, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Endocrinology clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.